HCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study
|
|
- Briana Nelson
- 5 years ago
- Views:
Transcription
1 Tram T. Tran, MD, FACG Approach to HCV Treatment in Patients with HCC Tram T. Tran, MD, FACG Professor of Medicine Medical Director, Liver Transplant Cedars Sinai Medical Center Natural History of HCV Infection Natural History of HCV Infection Acute Acute Infection Infection Clearance of Clearance of HCV HCV RNA RNA 15%-25% 15%-25% Chronic Chronic Infection Infection 75%-85% 75%-85% Extrahepatic Extrahepatic Manifestations Manifestations %-% %-% over over years years HCC HCC 1%-4% per year 1%-4% per year Decompensated Decompensated 5-yr survival rate 50% 5-yr survival rate 50% %-30% of individuals are symptomatic. %-30% of individuals are symptomatic. HCC=hepatocellular carcinoma. HCC=hepatocellular carcinoma. Adapted from Chen SL, Morgan J MedSci. Sci.06;3: ;3: Adapted from Chen SL, Morgan TR.TR. Int Int J Med Page 1 of 8
2 HCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study Cumulative Mortality (%) (%) Anti-HCV+, HCV RNA detectable Anti-HCV+, HCV RNA undetectable Anti-HCV All Causes Liver Cancer Extrahepatic Diseases All Causes Liver Cancer Extrahepatic Diseases (n=2394) (n=115) (n=2199) % % 18.4% % 11.0% % % % % Follow-Up (Years) Follow-Up (Years) Follow-Up (Years) (Years) (Years) (Years) REVEAL HCV: HCV: Risk Risk Evaluation Evaluation of Viral of Load Viral Elevation Load Elevation and Associated and Associated Liver Disease/Cancer Liver Disease/Cancer ( ). ( ). Anti-HCV seronegative (n=18,541); anti-hcv seropositive (n=95; detectable HCV RNA: 69.4%). Average follow-up: 16.2 years. Among Anti-HCV extrahepatic seronegative causes (n=18,541); of death, anti-hcv 68.5% seropositive and 69.3% (n=95; were detectable noncancer HCV deaths RNA: for 69.4%). HCV Average seronegative follow-up: and 16.2 seropositive, years. respectively. P<.001 Among extrahepatic for comparison causes among of death, all 68.5% 3 groups and and 69.3% P<.001 were noncancer for HCV RNA deaths detectable for HCV seronegative vs undetectable. and seropositive, respectively. Lee P<.001 M-H, for et et al. comparison al. J Infect J Infect Dis. among Dis. 12;6: all 3 groups and P<.001 for HCV RNA detectable vs undetectable. Regression of Advanced Fibrosis or by Transient Elastography (FibroScan) in SVR12 Patients Retrospective chart review of SVR12 and prospective transient elastography data after SVR12 (n=0) /F3-F4 (65%/35%) Regimens Sofosbuvir-based (45%), telaprevir + PR (29%), PR (16%), clinical trial/other (%) Overall median time to improvement: 2.5 years after SVR versus F3-F4: 3.0 versus 2.5 years Predictor of regression in F3-F4 at baseline: APRI (P<0.05) Surrogate marker of improvement of baseline cirrhosis: decrease in ALT (P=0.03) Crissien AM, et al. Hepatology. 15;62(suppl S1):264A-265A. Abstract 8. Patients (%) % Change in Fibrosis by Transient Elastography Improved No change Worsen 34% Overall (n=0) 6% 69% 14% 17% F3-F4 (n=35) 55% 45% 0% (n=65) Baseline Page 2 of 8
3 Global Epidemiology of Hepatocellular Carcinoma Global Epidemiology of Hepatocellular Carcinoma 3, ,000 deaths related to HCC/year deaths related to HCC/year Represents 5% of all cancer cases Great variability according to gender, age, and geographic areas Represents 5% of all cancer cases Great variability according to gender, age, and geographic areas Kiyosawa K, Jpn. J. Inf. Dis., 55, 69-77, 02 Risk Factors for HCC in Chronic HCV Risk Factors for HCC in Chronic HCV Older age Older age Duration of infection Duration of infection Male sex Race Male sex Alcohol Race Obesity Alcohol Diabetes HBV or HIV co-infection Obesity Absence of treatment Diabetes HBV or HIV co-infection Absence of treatment Page 3 of 8
4 HCV Related Related HCC HCC Incidence Incidence The Incidence and 5-Year Survival of HCC in United States ( ) The Incidence and 5-Year Survival of HCC in United States ( ) El-Serag HB. N Engl J Med 11 Page 4 of 8
5 HCV is the Dominant Risk Factors for HCC in the United States HCV is the Dominant Risk Factors for HCC in the United States HCV is the Dominant Risk Factors for HCC in the United States Di Bisceglie AM, et al.am J Gastroenterol. 03 Sep;98(9):60-3. Di Di BisceglieAM, AM, et et al.amj J Gastroenterol. 03 Sep;98(9):60-3. Hepatocellular Carcinoma Sustained Viral Responders vs. Non-responders Hepatocellular Carcinoma, % % P<.001 P<.001 Without SVR Without SVR With SVR With SVR Time, y JAMA, Dec 26, 12-vol 308,24,2589 Page 5 of 8
6 Higher Cancer Rates in HCV Patients: Real-World Evidence from a Large Health Maintenance Organization Higher Cancer Rates in HCV Patients: Real-World Evidence from a Large Health Maintenance Organization Cancer diagnosis diagnosis rate is higher rate is higher for for HCV HCV patients patients vs. non-hcv vs. patients, non-hcv even when patients, excluding even liver cancer when (p<0.001) excluding liver cancer (p<0.001) Univariate analysis analysis shows that shows cancer rates that were cancer significantly rates higher were for significantly liver cancer, higher for liver cancer, nonnon-hodgkin Hodgkin lymphomas, lymphomas, and total and cancer total sites cancer sites Cancer rates are higher in Cancer HCV rates patients; are higher these in HCV patients; results these suggest results suggest another another possible possible manifestation of HCV manifestation of HCV p<0.001; p<0.005 ALL SITES (W/O HCC) ALL SITES (W/ HCC) PROSTATE RENAL LUNG HEAD / NECK NON-HODGKIN LYMPHOMA CRUDE HCV vs. NON-HCV CANCER RATES CRUDE HCV vs. NON-HCV CANCER RATES MYELOMA PANCREAS LIVER COLON / RECTUM STOMACH ESOPHAGUS RATE RATIO (95% CI): HCV vs. NON-HCV Nyberg AH, EASL, 15, O058 Does treatment INCREASE HCC risk? 344 cirrhotic patients Treated with DAA, followed for 24 weeks SVR 91% HCC detected 7.6% overall 28% in those with previous HCC 3% in those with no history of HCC Multivariate analysis: Child-Pugh and prior HCC Conti F J Hepat Oct 16 Page 6 of 8
7 Abstract FRI-166 E.J. Lawitz 1, P. Ruane 2, C. Stedman 3, G. Foster 4, R.H. Hyland 5, S. Coogan 6, S. Moody 7, H. Dvory-Sobol 8, S.J. Knox 5, D.M. Brainard 5, A. Abergel 9, K. Agarwal, Z. Younes 11, C. Schwabe Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX 2. Ruane Medical and Liver Health Institute, Los Angeles, CA, United States 3. Christchurch Hospital, Christchurch, New Zealand 4. Blizard Institute, Queen Mary University of London, London, United Kingdom 5. Clinical Research, Gilead Sciences, Inc. 6. Clinical Operations, Gilead Sciences Inc., Foster City, CA 7. Pharpoint Research, Inc., Durham, NC 8. Clinical Virology, Gilead Sciences, Inc., Foster City, CA, United States 9. Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France. King s College Hospital, London, United Kingdom 11. Gastro One, Germantown, TN, United States 12. Auckland Clinical Studies, Auckland, New Zealand Objectives and Methods To determine long-term virologic and clinical outcomes in HCV patients treated with DAA regimens using registry study data Patients with chronic HCV treated in a Gilead-sponsored study were eligible for 1 of 2 ongoing 3-year registry studies SVR Registry: patients who achieved a sustained virologic response 12 weeks after treatment end (SVR12) in parent study Sequence Registry: patients with virologic failure in parent study Deep sequencing with 1% cutoff used Page 7 of 8
8 Outcomes SVR maintained in 99.7% (5414/5433) patients 6 patients (0.1%) virologic evidence of late relapse 12 patients (0.2%) virologic evidence of reinfection HCC was reported in 0.3% (16/5433) and 0.9% (5/536) of patients in the SVR and Sequence registries through Week 96 respectively. Summary Page 8 of 8
Viral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015
HEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015 Overview Understand the GLOBAL and US burden of chronic HCV infec
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationLa gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi. Simona Landonio I Div Mal inf H Sacco Milano
La gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi Simona Landonio I Div Mal inf H Sacco Milano HCV Natural History Viganò M et al Gastroenterology 27;133:835-842 Overall
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationThe Impact of DAA on HCC Occurrence
The Impact of DAA on HCC Occurrence Professeur Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital Paul Brousse Université Paris
More informationSuccessful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection
Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection Liz Highleyman Produced in collaboration with hivandhepatitis.com Published: 28 October 2015 Jump to Trends
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationAustralasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia
Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials J Grebely
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationTreatment of HCV in the Era of DAAs in Pakistan
PSH Clinical Guidelines Statement 2017 Treatment of HCV in the Era of DAAs in Pakistan Prof. Altaf Alam Professor of Gastroenterology-Hepatology Shaikh Zayed Postgraduate Medical Institute, Lahore. Pakistan
More informationHepatitis C in Dr. Michael Bays D.O.
Hepatitis C in 2015 Dr. Michael Bays D.O. HCV Virology Member of the Flavivirus family (Yellow Fever, Dengue) Hepacivirus genus Enveloped, positive, singlestranded RNA virus 9.6 Kb genome encodes a single
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationHCV Treat now! Robert G Gish MD. Professor Consultant Stanford University
HCV Treat now! Robert G Gish MD Professor Consultant Stanford University Steering committee and Executive Board NVHR National Viral Hepatitis Roundtable Founding Member CEVHAP Singapore Viral Hepatitis
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationThe Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study
The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study DK Li, YJ Ren, DS Fierer, S Rutledge, OS Shaikh, V Lo
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationHepatitis C - results in real life
Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationThe long term impact of treatment on the outcome of liver disease?
The long term impact of treatment on the outcome of liver disease? Y.Yazdanpanah, MD, PhD INSERM, Atip/avenir U738, Univ Paris Diderot, Sorbonne Paris Cité, France Service des maladies infectieuses et
More informationManagement of HCV Tawesak Tanwandee
Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to
More informationJong Young Choi, M.D.
The Liver Week 2014 Jong Young Choi, M.D. Dept. of Internal Medicine The Catholic University of Korea, College of Medicine The clinical study for natural history of LC is not many. Most of them was done
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationTreatment of chronic hepatitis delta Case report
Treatment of chronic hepatitis delta Case report George Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National and Kapodistrian University of Athens, Director of Academic Department
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationHepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
More informationZobair M. Younossi M.D., M.P.H., FACG
HCV Epidemiology and Cohort Screening Guidelines Zobair M. Younossi, MD, MPH, FACG Consultant or Advisor: Conatus, Enterome, Gilead, Merck, Salix, Vertex, J & J HCV Epidemiology and Cohort Screening Guidelines
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationDr Kate Childs. King s College Hospital NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Kate Childs King s College Hospital NHS Foundation Trust, London 1-4 April 2014, Arena and Convention Centre Liverpool Decrease in both IP-10 and 25(OH)D
More informationLiver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:
More information